Introduction
============

Alzheimer's disease (AD) is the most common form of dementia ([@B4]). It is characterized by the accumulation of extracellular plaques of amyloid-beta (Aβ) protein ([@B36]) and intracellular neurofibrillary tangles formed by hyperphosphorylated and/or aggregated tau protein ([@B39]). In addition, AD is accompanied by prominent neuronal and synaptic loss ([@B11]). Together, these hallmarks lead to the characteristic neurodegeneration observed in this disease. Assays for the detection of proteins related to the main pathological characteristics of the disease, such as neurofibrillary tangles, amyloid plaques, and neuronal death have been developed. In this regard, the prevalence of the biomarkers identified was then tested in cerebrospinal fluid (CSF) samples from AD patients and controls ([@B8]). CSF of the former showed a lower amount of Aβ42 and a higher level of tau ([@B33]; [@B18]; [@B5]).

Inflammation is associated with AD ([@B10]). However, whether inflammation is a cause or a consequence of the development or progression of the disease is unknown. Inflammation in the central nervous system (CNS) is regulated mainly by microglia ([@B41]). To maintain brain homeostasis, these cells, which are in charge of CNS surveillance, establish continuous communication with other types of brain cells, such as neurons and astrocytes, through the expression, interaction and secretion of chemokines, among other molecules ([@B32]). Chemokines have several functions in the CNS, including the mediation of cell to cell communication, during development and in adulthood ([@B29]). CX3 chemokine ligand 1 (CX3CL1), also named fractalkine, is expressed by neurons as membrane-bound and soluble forms ([@B6]). This chemokine interacts with the CX3 chemokine receptor 1 (CX3CR1) present in microglia ([@B23]; [@B27]). Therefore, there is a direct communication axis between neurons and microglia performed by the CX3CL1/CX3CR1 tandem ([@B21]; [@B37]). Furthermore, neurons modulate microglial function through the CX3CL1/CX3CR1 axis ([@B31]). It has been suggested that this axis is impaired with aging and in neurological diseases such as AD ([@B37]; [@B9]).

Given the presence of inflammation in AD, we studied whether CX3CL1 is altered with the progression of the disease. To this end, we used CSF and plasma samples from control subjects, patients with mild cognitive impairment (MCI), and patients with AD dementia.

Material and Methods
====================

Study Participants
------------------

We analyzed 42 CSF derived from control, MCI and AD subjects and 28 plasma samples derived from the same control and AD donors. Participants were recruited in the Hospital de la Santa Creu i Sant Pau, Barcelona, as part of the cohort of the Sant Pau Initiative on Neurodegeneration (SPIN) (Alcolea D, submitted). Ethic committee number 16/2013.

Participants had a diagnosis of MCI due to AD, AD dementia with evidence of the pathophysiological process ([@B17]; [@B30]), or were cognitively normal controls. All participants had CSF and blood samples available, which were obtained at the same time.

All AD patients had abnormal values of Aβ~42~, total tau (tau) and phospho-tau (ptau) and all controls had normal values (**Table [1](#T1){ref-type="table"}**). All participants underwent a complete neuropsychological evaluation using a previously published protocol ([@B15]). Furthermore, they all gave written informed consent to participate in the study. The local ethics committee at Sant Pau Hospital approved the study. Participants were selected from a group of donors that were free of inflammatory disorders and had not drug therapy that confounding effect on inflammation. The absence of inflammation was confirmed by blood analysis from the blood extracted from donors.

###### 

Demographics and CSF biomarker levels of the participant.

  Group     Cases (*N*)   Age (Mean years ± SD)   Gender (female/male)   MMSE ± SD       CSF ABETA42 (pg/ml) ± SD   CSF P-TAU (pg/ml) ± SD   CSF TAU (pg/ml) ± SD   CX3CL1 (ng/ml) ± SD
  --------- ------------- ----------------------- ---------------------- --------------- -------------------------- ------------------------ ---------------------- ---------------------
  Control   14            64 ± 2.92               7/8                    29 ± 0.88       802 ± 218                  59 ± 42                  244 ± 46               0.31 ± 0.05
  MCI       14            70 ± 3.52^∗∗∗^          9/5                    26 ± 2.95^∗∗^   438 ± 58^∗∗∗^              112 ± 51^∗^              761 ± 374 n.s          0.28 ± 0.07
  AD        14            68 ± 4.18^∗^            9/5                    21.5 ± 3.5      453 ± 101^∗∗∗^             109 ± 46^∗^              762 ± 377 n.s          0.166 ± 0.05^∗∗∗^

Three groups of samples: C, control; MCI, mild cognitive impairment; AD, Alzheimer's disease, with 14 cases (N) in each group, were analyzed. The average age, gender, memory test (MMSE), amount of CSF Aβ42, CSF ptau, CSF tau and CSF CX3CL1 are detailed in the table. Results are expressed as average concentration ± standard deviation (SD). Statistics of the measures are related to control:

∗

p ≤ 0.05,

∗∗

p ≤ 0.01, and

∗∗∗

p ≤ 0.001.

CSF Analysis
------------

Core AD biomarkers \[Aβ~42~, total tau (tau) and phospho-tau (ptau)\] were analyzed at the Hospital Sant Pau using commercially available ELISA kits (Innotest^TM^ β-Amyloid~1-42~, Innotest^TM^hTAU Ag, and Innotest^TM^ Phospho-tau~181P~; Fujirebio-Europe, Ghent, Belgium), following the manufacturer's instructions. The cut-off values for normal core AD biomarkers were Aβ~42~ \> 550 pg/ml, tau \< 350 pg/ml, and ptau \< 61 pg/ml ([@B2]).

Human CX3CL1 ELISA
------------------

The total amount of CX3CL1 present in CSF derived from control, MCI and AD dementia samples or from plasma derived from control and AD dementia samples was analyzed by ELISA (R&D Systems, United States, catalog number DCX310), following the manufacturer's instructions. Each sample was tested in duplicate. The results were expressed as concentration of CX3CL1 (ng/ml). The mean of the coefficient of variation (CV) of sample duplicates is 6.19% and the CV between-plates is 9.69%. The mean of the limit of detection (LOD) of this ELISA is 0.018 ng/ml (range: 0.006--0.072 ng/ml), as indicated by the manufacturer's instructions as "mean of minimum detectable dose of human fractalkine." Samples analyzed were over the LOD. In addition, the lower limit of quantification (LLOQ) was calculated as blank + 9 SD of the blank, obtained a LLOQ = 0.063 and CV = 18.24%. Only samples which values were \> LLOQ were analyzed.

Statistical Analysis
--------------------

The Kolmogorov--Smirnov test was used to test the normality of the sample distribution. Data were analyzed by a Student's *t*-test, because the distribution was normal, or by one-way analysis of variance. *Post hoc* comparisons were analyzed using Tukey's multiple comparison test. Differences were considered statistically significant when the probability, *p*, of the null hypothesis was ≤ 0.05. Data are presented as the means ± SE.

Results
=======

Forty-two CSF samples were analyzed in this study (**Table [1](#T1){ref-type="table"}**). Demographic and CSF markers are detailed in **Table [1](#T1){ref-type="table"}**.

CX3CL1 in CSF Decreases in AD
-----------------------------

We have previously shown that the amount of total CX3CL1 increases in AD brains with the progression of the disease ([@B9]). To analyze whether this difference in CSF, we measured the amount of CX3CL1 by ELISA. Three groups of CSF samples (**Table [1](#T1){ref-type="table"}**): control, MCI and AD dementia were tested. One sample from the AD group was eliminated for statistical proposes because was lower than the LLOQ. There was no difference between controls and MCI (C = 0.31 ± 0.05 ng/ml vs. MCI = 0.28 ± 0.07 ng/ml; *p* = 0.198) (**Figure [1A](#F1){ref-type="fig"}** and **Table [1](#T1){ref-type="table"}**). However, a marked decrease in the concentration of CX3CL1 was observed between MCI and AD dementia (MCI = 0.28 ± 0.07 ng/ml vs. AD = 0.166 ± 0.05 ng/ml; ^∗∗^*p* \< 0.01). Furthermore, a clear decrease in CX3CL1 concentration was also found when control and AD dementia samples were compared (C = 0.31 ± 0.05 ng/ml vs. AD = 0.166 ± 0.05 ng/ml; ^∗∗∗^*p* \< 0.0001). Therefore, a reduction of CX3CL1 was observed in AD dementia.

![CX3CL1 decreases in the CSF of AD patients. *N* = 14 samples per group: control (C), mild cognitive impairment (MCI), and Alzheimer's disease (AD) were analyzed by ELISA of CX3CL1. Samples were run in duplicate. The concentration of CX3CL1 was analyzed in CSF **(A)** and plasma samples **(B)**. CX3CL1 decreased in the CSF of AD compared to control and MCI **(A)**. However, no difference was observed in the concentration of CX3CL1 in plasma samples **(B)**. Bars show means ± SE. ^∗∗^*p* ≤ 0.01, ^∗∗∗^*p* ≤ 0.001.](fnins-12-00609-g001){#F1}

Next, the amount of CX3CL1 was measured in plasma. Because the amount of CX3CL1 in CSF didn't change in MCI compared to control subjects, we focus the measure on samples from control subjects and AD dementia patients. No differences between groups were detected (C = 0.75 ± 0.027 ng/ml vs. AD = 0.72 ± 0.032 ng/ml; *p* = 0.782) (**Figure [1B](#F1){ref-type="fig"}**). These results confirmed that the variation of CX3CL1derives from changes within the CNS and not in the periphery.

Discussion
==========

Here, we show for the first time that neuronal CX3CL1 is decreased in the CSF samples from AD dementia patients compared to those from control subjects. Furthermore, the concentration of CX3CL1 is reduced in AD dementia compared to MCI samples but not in MCI compared to C samples. Therefore, decreased levels of CX3CL1 are more evident in advanced stages (dementia).

CX3CL1 is a chemokine expressed mainly in neurons in the CNS ([@B32]). In these cells, it is present as a membrane-bound protein and, after its excision by alpha-secretases such as ADAM10 ([@B22]) and ADAM17 ([@B19]), among others, it is secreted as a soluble form. This effect is also observed for the amyloid precursor protein (APP), which is cleaved by ADAM10 within the Aβ domain, thus preventing Aβ generation ([@B26]). Soluble CX3CL1 has a chemoattractive effect for monocytes, natural killer cells, and lymphocyte cells ([@B6]; [@B13]). However, the exact role of each isoform remains unknown. Both isoforms of the chemokine mediate their effects by interaction with the CX3CR1 receptor, which is expressed exclusively by microglia ([@B21]). The interaction between CX3CL1 and CX3CR1 has both beneficial and detrimental consequences throughout the activation of various pathways within microglia ([@B23]; [@B35]). It has been proposed that the binding of CX3CL1 to CX3CR1 maintains microglia in a resting state, thereby decreasing the production of pro-inflammatory cytokines and preventing the activation response by these cells ([@B7]). Therefore, correct functionality of the CX3CL1/CX3CR1 axis is crucial for the maintenance of brain homeostasis, and especially for dealing with microglia-mediated inflammation in the CNS ([@B14]). In this regard, we have recently detected an imbalance in the CX3CL1/CX3CR1 axis at later stages of AD dementia ([@B9]). Furthermore, this imbalance has been reported in other diseases ([@B37]). In addition, both CX3CL1 and CX3CR1 increase in later stages of AD dementia ([@B9]). Here, we report a decrease in CX3CL1 in the CSF of AD dementia patients compared to that of control subjects. This decreased CX3CL1 corresponds to the soluble form of the protein (∼70 kDa in western blot, data not shown), which is the form that is secreted. In this regard, ADAM10 activity decreases in AD dementia ([@B25]; [@B34]; [@B28]), thereby allowing the cleavage of APP by beta and gamma-secretases, thus leading to Aβ peptide, which is the toxic protein accumulated in AD dementia brains ([@B16]). Therefore, we hypothesize that, during the progression of AD dementia, the expression of a membrane-bound and less soluble form of CX3CL1 in the brain increases as a result of reduced ADAM10 activity. This increase is reflected by a decrease in the secretion of soluble CX3CL1 into the CSF of AD dementia patients compared to controls and MCI subjects.

Changes in CX3CL1 concentration have been found in other diseases that course with inflammation. For example, soluble CX3CL1 levels are increased in plasma and CSF of patients with lupus erythematosus ([@B20]). In addition, plasma CX3CL1 levels are augmented in individuals with type-2 diabetes ([@B38]). In this regard, we did not find any difference in this parameter in the plasma samples from AD dementia patients compared to those from control subjects. Recently, other proteins related to microglia and astrocytes, such as TREM2 ([@B40]) and YKL-40, have been put forward as potential biomarkers for AD ([@B1], [@B2], [@B3]). Furthermore, and in the same context as our work, a recent study has described the clinical use of inflammatory CSF protein markers in AD dementia ([@B12]). In that study, the authors analyzed several cytokines and other factors related to inflammation in the CSF of AD dementia patients. They found changes when compared with control samples. Although we did not find any difference in the levels of CX3CL1 CSF between MCI and C samples, a marked difference was detected at the advanced stage of dementia.

Decreased levels of Aβ42 and increased amounts of tau and ptau in the CSF of AD dementia patients are considered biomarkers for the disease ([@B24]). In addition, changes in CX3CL1 were detected in AD compared to MCI CSF samples and not in control compared to MCI. Overall, our results show that changes in the concentration of CX3CL1 could be a novel target to be explored in the context of inflammation and AD.
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